Search - tctmd.com

Displaying 321 - 340 of 403

Sort: Relevancy | Date

Presentation

Risk of Adverse Cardiac and Bleeding Events Following Surgery in Patients With Stents

Presenter: Francesco Saia

December 07, 2015

News Daily News

¿Adiós SMD? Nuevos Análisis de la DAPT Evidencian Menos Ocurrencias de Trombosis del Stent Con el SLF

Yael L. Maxwell

October 26, 2015

News Daily News

Goodbye BMS? New DAPT Analysis Shows Less Stent Thrombosis With DES

Yael L. Maxwell

October 26, 2015

News Daily News

BMS 再见？新 DAPT 分析显示 DES 支架血栓形成率较低

Yael L. Maxwell

October 26, 2015

Presentation

Stent Thrombosis in DES or BMS in Patients Receiving Dual Antiplatelet Therapy

Presenter: Dean J. Kereiakes

October 22, 2015

News Industry News

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Daily News

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES 亚组研究：实践变化可能会进一步降低已处于低水平的支架血栓发生率

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

Presentation

Fixed and Modifiable Correlates of DES Thrombosis From a Large All-Comers Registry

Presenter: Bruce R. Brodie

October 08, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

News Daily News

Subestudio BASKET-PROVE: Los SLF son Mejores que los SMD en Pacientes Ancianos con Arterias Grandes

Yael L. Maxwell

July 29, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

BASKET-PROVE 亚组研究：DES 对有大动脉的老年患者的治疗效果优于 BMS

Yael L. Maxwell

July 29, 2015

News Daily News

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Yael L. Maxwell

July 29, 2015

News Industry News

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

July 23, 2015

News Industry News

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

July 22, 2015

News Industry News

Symic Biomedical Selects Vascular Clinical Candidate

July 20, 2015

Advertisement

Risk of Adverse Cardiac and Bleeding Events Following Surgery in Patients With Stents

¿Adiós SMD? Nuevos Análisis de la DAPT Evidencian Menos Ocurrencias de Trombosis del Stent Con el SLF

Goodbye BMS? New DAPT Analysis Shows Less Stent Thrombosis With DES

BMS 再见？新 DAPT 分析显示 DES 支架血栓形成率较低

Stent Thrombosis in DES or BMS in Patients Receiving Dual Antiplatelet Therapy

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

ADAPT-DES 亚组研究：实践变化可能会进一步降低已处于低水平的支架血栓发生率

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Fixed and Modifiable Correlates of DES Thrombosis From a Large All-Comers Registry

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Subestudio BASKET-PROVE: Los SLF son Mejores que los SMD en Pacientes Ancianos con Arterias Grandes

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

BASKET-PROVE 亚组研究：DES 对有大动脉的老年患者的治疗效果优于 BMS

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

Symic Biomedical Selects Vascular Clinical Candidate

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content